

Can 200 IU of hCG replace recombinant FSH in the late GnRH-antagonist cycle? A pilot study

Human Reproduction

24, 2910-2916

DOI: [10.1093/humrep/dep253](https://doi.org/10.1093/humrep/dep253)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Chorionic gonadotropin and luteinizing hormone supplementation during ovarian stimulation. , 0, , 151-161.		0
3	Ovarian Hyperstimulation Syndrome Prevention Strategies: Individualizing Gonadotropin Dose. Seminars in Reproductive Medicine, 2010, 28, 463-467.	0.5	10
4	Mild ovarian stimulation for IVF: 10 years later. Human Reproduction, 2010, 25, 2678-2684.	0.4	123
5	Cyclooxygenase-2 network as predictive molecular marker for clinical pregnancy in in vitro fertilization. Fertility and Sterility, 2011, 95, 448-451.e2.	0.5	6
6	Conventional ovarian stimulation no longer exists: welcome to the age of individualized ovarian stimulation. Reproductive BioMedicine Online, 2011, 23, 141-148.	1.1	35
7	No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part I, corifollitropin alfa. Reproductive BioMedicine Online, 2011, 23, 449-456.	1.1	22
8	Agonists or antagonists for ovarian stimulation?. , 0, , 80-86.		0
9	Gene expression profile in the endometrium on the day of oocyte retrieval after ovarian stimulation with low-dose hCG in the follicular phase. Molecular Human Reproduction, 2011, 17, 33-41.	1.3	14
10	A randomized controlled doseâ€“response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Human Reproduction, 2012, 27, 3074-3084.	0.4	43
11	Impact of 'LH activity' supplementation on serum progesterone levels during controlled ovarian stimulation: a systematic review. Human Reproduction, 2012, 27, 232-243.	0.4	26
12	An unfortunate resurgence of human chorionic gonadotropin use for weight loss. International Journal of Obesity, 2012, 36, 385-386.	1.6	3
13	Ovarian Stimulation: Today and Tomorrow. Current Pharmaceutical Biotechnology, 2012, 13, 392-397.	0.9	32
14	Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trial. Journal of Assisted Reproduction and Genetics, 2012, 29, 1213-1220.	1.2	6
15	Successful pregnancy following low-dose hCG administration in addition to hMG in a patient with hypothalamic amenorrhea due to weight loss. Gynecological Endocrinology, 2012, 28, 460-462.	0.7	1
16	Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis. Fertility and Sterility, 2012, 97, 1343-1350.e3.	0.5	7
17	Addition of low dose hCG to rFSH benefits older women during ovarian stimulation for IVF. Reproductive Biology and Endocrinology, 2012, 10, 55.	1.4	9
18	Efficacy of low-dose hCG in late follicular phase in controlled ovarian stimulation using GnRH agonist protocol. Archives of Gynecology and Obstetrics, 2012, 286, 771-775.	0.8	7
19	Live-birth rates after HP-hMG stimulation in the long GnRH agonist protocol: association with mid-follicular hCG and progesterone concentrations, but not with LH concentrations. Gynecological Endocrinology, 2013, 29, 46-50.	0.7	6

#	ARTICLE	IF	CITATIONS
20	FSH replaced by low-dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. The Cochrane Library, 2013, , CD010042.	1.5	17
21	Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin-releasing hormone agonist short regimen on alternate days and an antagonist protocol for assisted fertilization treatments. Fertility and Sterility, 2013, 99, 1615-1622.	0.5	15
22	Live birth rates after IVF are reduced by both low and high progesterone levels on the day of human chorionic gonadotrophin administration. Human Reproduction, 2014, 29, 1698-1705.	0.4	76
23	Pelvic Imaging in Reproductive Endocrinology. , 2014, , 851-889.e11.		0
24	Medical Approaches to Ovarian Stimulation for Infertility. , 2014, , 701-733.e8.		2
25	Serum estradiol level change after human chorionic gonadotropin administration had no correlation with live birth rate in IVF cycles. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 178, 177-182.	0.5	12
26	Luteinizing hormone and human chorionic gonadotropin: a review of their varied clinical applications in assisted reproductive technology. Expert Review of Endocrinology and Metabolism, 2015, 10, 87-100.	1.2	4
27	Major drawbacks and additional benefits of agonist trigger“ not ovarian hyperstimulation syndrome related. Fertility and Sterility, 2015, 103, 874-878.	0.5	29
28	Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. Human Reproduction, 2015, 30, 2387-2395.	0.4	40
29	Control of the Menstrual Cycle. , 2015, , 1307-1361.		11
30	Can we modify assisted reproductive technology practice to broaden reproductive care access?. Fertility and Sterility, 2016, 105, 1138-1143.	0.5	18
31	To delay or not to delay a frozen embryo transfer after a failed fresh embryo transfer attempt?. Fertility and Sterility, 2016, 105, 1202-1207.e1.	0.5	34
32	Low-dose human chorionic gonadotropin alone can complete follicle maturity: successful application to modified natural cycle in Vitro fertilization. Fertility and Sterility, 2016, 105, 1228-1231.	0.5	9
34	Concomitant use of FSH and low-dose recombinant hCG during the late follicular phase versus conventional controlled ovarian stimulation for intracytoplasmic sperm injection cycles. Human Fertility, 2017, 20, 285-292.	0.7	1
35	The dilemma of counseling patients about poor prognosis: live birth after IVF with autologous oocytes in a 43-year-old woman with FSH levels above 30 mIU/mL. Journal of Assisted Reproduction and Genetics, 2017, 34, 1185-1188.	1.2	2
36	Grand Challenges in Reproductive Endocrinology. Frontiers in Endocrinology, 2016, 7, 169.	1.5	2
37	Medical Approaches to Ovarian Stimulation for Infertility. , 2019, , 743-778.e7.		3
38	Replacing HMG/FSH by low-dose HCG to complete corifollitropin alfa stimulation reduces cost per clinical pregnancy: a randomized pragmatic trial. Reproductive BioMedicine Online, 2020, 40, 468-474.	1.1	2

#	ARTICLE	IF	CITATIONS
39	Tissue-Engineered Ovary. Reference Series in Biomedical Engineering, 2021, , 285-313.	0.1	0
40	Progesterone levels predict pregnancy outcomes in individuals with fallopian tube associated infertility. BMC Pregnancy and Childbirth, 2021, 21, 16.	0.9	2
41	Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers. Scientific Reports, 2021, 11, 6404.	1.6	0
42	A Randomized Controlled Trial on the Efficacy and Safety of Low-Dose hCG in a Short Protocol with GnRH Agonist and Ovarian Stimulation with Recombinant FSH (rFSH) During the Follicular Phase in Infertile Women Undergoing ART. Reproductive Sciences, 2022, 29, 497-505.	1.1	2
43	Ovarian Stimulation for IVF: Mild Approaches. Methods in Molecular Biology, 2014, 1154, 305-328.	0.4	11
44	How to Improve your ART Success Rates. , 2011, , .		5
45	Reintroducing serum FSH measurement during ovarian stimulation for ART. Reproductive BioMedicine Online, 2022, 44, 548-556.	1.1	2
46	Tissue Engineered Ovary. , 2020, , 1-29.		0
47	Optimisation of the follicular phase in IVF/ICSI. Facts, Views & Vision in ObGyn, 2012, 4, 203-12.	0.5	3
48	The two-step process of ovarian follicular growth and maturation in mammals can be compared to a fruit ripening where quality depends on the second step. Biology of Reproduction, 2022, 106, 230-234.	1.2	1
49	How to read a Cochrane Review. , 0, , 247-253.		0
50	Ectopic pregnancy and failed oocyte retrieval during <i>in vitro</i> fertilization stimulation: Two case reports. World Journal of Clinical Cases, 0, 10, 10310-10316.	0.3	0